Search company, investor...
Search
Kiniksa Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kiniksa.com

Stage

IPO | IPO

Date of IPO

5/25/2018

Market Cap

0.80B

Stock Price

11.51

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering or acquiring, developing, and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need.

Kiniksa Pharmaceuticals Headquarters Location

Clarendon House 2 Church Street

Hamilton, HM 11,

Bermuda

781-431-9100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Kiniksa Pharmaceuticals Patents

Kiniksa Pharmaceuticals has filed 16 patents.

The 3 most popular patent topics include:

  • Immunology
  • Monoclonal antibodies
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/19/2021

5/10/2022

Monoclonal antibodies, Clusters of differentiation, Intensive care medicine, Immunology, Syndromes

Grant

Application Date

5/19/2021

Grant Date

5/10/2022

Title

Related Topics

Monoclonal antibodies, Clusters of differentiation, Intensive care medicine, Immunology, Syndromes

Status

Grant

Latest Kiniksa Pharmaceuticals News

Rapid itch reduction seen with ruxolitinib cream

Sep 20, 2022

Disclosures: Kwatra reports serving as an advisory board member or consultant for AbbVie, Galderma, Incyte Corporation, Kiniksa Pharmaceuticals, Regeneron Pharmaceuticals and Pfizer Inc; and receiving grant funding from Pfizer Inc., Galderma and Kiniksa Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio In patients with atopic dermatitis, ruxolitinib cream significantly reduced itch during two phase 3 trials. The randomized, double blind, vehicle controlled, identical design TRuE AD 1 and TRuE AD 2 studies included 1,249 patients aged 12 years or older who had AD for at least 2 years, an IGA of 2 or 3 and 3% to 20% body surface area affected. In patients with atopic dermatitis, ruxolitinib cream significantly reduced itch during two phase 3 trials. Patients were randomly assigned 2:2:1 to receive twice daily ruxolitinib cream 0.75%, 1.5% ruxolitinib cream or vehicle for 8 weeks. Shawn G. Kwatra “What is interesting is there were assessments for itch using the itch numerical rating scale that were evaluated with an electronic diary that was completed by the patient in the evenings,” Shawn G. Kwatra, MD, associate professor of dermatology and director of the Itch Center at Johns Hopkins University and one of the study’s investigators, told Healio. “We were able to follow the improvements in itch over time and see how significant itch reduction was.” Within 12 hours of first application, a reduction in itch of –0.4 and –0.5 points was reported by both ruxolitinib cream cohorts , which was a statistically significant reduction compared with vehicle, which recorded a change of –0.1 points. At week 8, 58.3% and 65.1% of the two treatment groups experienced at least a 2-point itch reduction as measured by the NRS2, compared with 29.4% of those in the vehicle group. A reduction of at least 4 points was achieved by 8.9% and 11.2% of the treatment groups, respectively, at day 2, compared with 2.1% of those in the vehicle group. By week 8, a 4-point reduction was reported by 41.5% and 51.5% of the ruxolitinib cohorts and 15.8% of the vehicle group. The mean NRS score decreased throughout the study from 5.1 in the total population to 2 in the 0.75% ruxolitinib group, 1.8 in the 1.5% ruxolitinib group and 3.5 in the vehicle group at day 56. At week 8, approximately 80% of those in either treatment cohorts had reduced itch as assessed by the VAS itch component of SCORAD, whereas 48% of the vehicle group experienced reduced itch. “Since itch is the cardinal symptom of atopic dermatitis that drives the negative quality of life, disrupting that itch/scratch cycle is really important for any medications,” Kwatra said. “Ruxolitinib cream results in a very rapid itch relief and it is sustained for a longer period of time. It is a very helpful and much needed addition to the armamentarium for the management of patients with atopic dermatitis.” Read more about

Kiniksa Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kiniksa Pharmaceuticals Rank

  • Where is Kiniksa Pharmaceuticals's headquarters?

    Kiniksa Pharmaceuticals's headquarters is located at Clarendon House, Hamilton.

  • What is Kiniksa Pharmaceuticals's latest funding round?

    Kiniksa Pharmaceuticals's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.